Novel targets for the prevention of osteoporosis – lessons learned from studies of metabolic bone disorders

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert opinion on therapeutic targets

• Publication date

  2015-05-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728222.2015.1045415PMID 25960169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways

  2015cited by this paper
• Efficacy, effectiveness and side effects of medications used to prevent fractures

  2015cited by this paper
• A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

  2015cited by this paper
• Faculty Opinions recommendation of PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis.

  2015cited by this paper
• Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

  2015cited by this paper
• Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

  2015influential reference
• Tissue‐Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody

  2014cited by this paper
• Romosozumab in postmenopausal women with low bone mineral density

  2014cited by this paper
• New therapeutics for osteoporosis.

  2014cited by this paper
• A Comparison of Osteoclast-Rich and Osteoclast-Poor Osteopetrosis in Adult Mice Sheds Light on the Role of the Osteoclast in Coupling Bone Resorption and Bone Formation

  2014cited by this paper
• PDGF-BB secreted by preosteoclasts induces CD31hiEmcnhi vessel subtype in coupling osteogenesis

  2014cited by this paper
• Novel approaches to the treatment of osteoporosis.

  2014cited by this paper
• Effect of ONO‐5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2‐Year Results From the OCEAN Study

  2014influential reference
• Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases

  2014cited by this paper
• A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record

  2014cited by this paper
• Romosozumab in postmenopausal women with osteopenia.

  2014cited by this paper
• Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures

  2014cited by this paper
• Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

  2014cited by this paper
• AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.

  2014cited by this paper
• Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.

  2014cited by this paper
• Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.

  2014cited by this paper
• Bone Histomorphometry of Transiliac Paired Bone Biopsies After 6 or 12 Months of Treatment With Oral Strontium Ranelate in 387 Osteoporotic Women: Randomized Comparison to Alendronate

  2014cited by this paper
• Inhibition of Cathepsin K Increases Modeling‐Based Bone Formation, and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys

  2014cited by this paper
• Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.

  2013cited by this paper
• Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.

  2013cited by this paper
• Osteoclast-Derived Coupling Factors in Bone Remodeling

  2013cited by this paper
• Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers

  2013cited by this paper
• Autosomal dominant osteopetrosis revisited: lessons from recent studies.

  2013cited by this paper
• Sphingosine 1-Phosphate (S1P) Receptors 1 and 2 Coordinately Induce Mesenchymal Cell Migration through S1P Activation of Complementary Kinase Pathways*

  2013cited by this paper
• To Wnt or not to Wnt: the bone and joint health dilemma

  2013cited by this paper
• Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury.

  2013cited by this paper
• Parathyroid hormone-related protein: an update.

  2012cited by this paper
• Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

  2012cited by this paper
• A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts.

  2012cited by this paper
• Inhibition of Cathepsin K for Treatment of Osteoporosis

  2012cited by this paper
• Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

  2012influential reference
• Ronacaleret, a calcium‐sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women

  2012cited by this paper
• Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis.

  2011cited by this paper
• Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis.

  2011influential reference
• An update on primary hip osteoarthritis including altered Wnt and TGF-β associated gene expression from the bony component of the disease.

  2011cited by this paper
• Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

  2011cited by this paper
• Safety and efficacy of the cathepsin K inhibitor ONO‐5334 in postmenopausal osteoporosis: The OCEAN study

  2011influential reference
• Osteoporosis: now and the future

  2011cited by this paper
• JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats.

  2011cited by this paper
• Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

  2010influential reference
• Severe developmental bone phenotype in ClC-7 deficient mice.

  2010cited by this paper
• Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.

  2010cited by this paper
• Of mice and men: divergent risks of teriparatide-induced osteosarcoma

  2010cited by this paper
• Sclerostin: Current Knowledge and Future Perspectives

  2010cited by this paper
• Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

  2010cited by this paper
• Sustained cyclic AMP production by parathyroid hormone receptor endocytosis.

  2009cited by this paper
• Targeted disruption of the Cl−/HCO3− exchanger Ae2 results in osteopetrosis in mice

  2009cited by this paper
• Bone density, strength, and formation in adult cathepsin K (-/-) mice.

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

  2009cited by this paper
• Expression and regulation of cathepsin K in skin fibroblasts

  2009cited by this paper
• Chapter 38. Epidemiology of Osteoporotic Fractures

  2009cited by this paper
• Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density

  2009cited by this paper
• Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate

  2008cited by this paper
• Cathepsin K in melanoma invasion.

  2008cited by this paper
• New mechanisms and targets in the treatment of bone fragility.

  2007cited by this paper
• The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.

  2007cited by this paper
• Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation.

  2007cited by this paper
• Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity?

  2007cited by this paper
• Safety and tolerability of subcutaneous PTHrP(1–36) in healthy human volunteers: a dose escalation study

  2006cited by this paper
• Bone quality--the material and structural basis of bone strength and fragility.

  2006influential reference
• Molecular Pathogenesis of Genetic and Inherited Diseases Acidification of the Osteoclastic Resorption Compartment Provides Insight into the Coupling of Bone Formation to Bone Resorption

  2005influential reference
• Loss of the chloride channel ClC‐7 leads to lysosomal storage disease and neurodegeneration

  2005cited by this paper
• Continuous PTH and PTHrP Infusion Causes Suppression of Bone Formation and Discordant Effects on 1,25(OH)2Vitamin D

  2005cited by this paper
• Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.

  2005cited by this paper
• Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.

  2005cited by this paper
• The Chloride Channel Inhibitor NS3736 Prevents Bone Resorption in Ovariectomized Rats Without Changing Bone Formation

  2004cited by this paper
• Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II.

  2004cited by this paper
• Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

  2004cited by this paper
• The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

  2003cited by this paper
• Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.

  2003cited by this paper
• Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

  2003cited by this paper
• [Epidemiology of osteoporotic fractures].

  2003cited by this paper
• Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.

  2002cited by this paper
• High bone density due to a mutation in LDL-receptor-related protein 5.

  2002cited by this paper
• High bone density due to a mutation in LDL-receptor-related protein 5.

  2002cited by this paper
• Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation.

  2001cited by this paper
• Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man.

  2001cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

  2001cited by this paper
• Determination of Bone Markers in Pycnodysostosis: Effects of Cathepsin K Deficiency on Bone Matrix Degradation

  1999cited by this paper
• Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

  1999cited by this paper
• Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.

  1998cited by this paper
• The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases*

  1998cited by this paper
• Novel Approaches to Treatment of Osteoporosis

  1998influential reference
• Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts (*)

  1996cited by this paper
• Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency

  1996cited by this paper
• Primer on the metabolic bone diseases and disorders of mineral metabolism

  1994cited by this paper
• Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis.

  1993cited by this paper
• Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types.

  1989cited by this paper
• Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects.

  1989cited by this paper
• Autosomal dominant osteopetrosis: An otoneurological investigation of the two radiological types

  1988cited by this paper
• The FASEB Journal express article 10.1096/fj.05-4221fje. Published online August 25, 2005. ©2005 FASEB

  year unknowncited by this paper

• Regulation of pain neurotransmitters and chondrocytes metabolism mediated by voltage-gated ion channels: A narrative review

  2023cites this paper
• MiR-655-3p inhibits the progression of osteoporosis by targeting LSD1 and activating BMP-2/Smad signaling pathway

  2020cites this paper
• G protein‐coupled receptors as anabolic drug targets in osteoporosis

  2017cites this paper
• Identification of biallelic LRRK1 mutations in osteosclerotic metaphyseal dysplasia and evidence for locus heterogeneity

  2016cites this paper
• A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.

  2016cites this paper